C. Bregengård

IS THE TRH TEST NECESSARY?

C. Kirkegaard, C. Bregengård, 1985, The Lancet.

The influence of free fatty acids on the free fraction of thyroid hormones in serum as estimated by ultrafiltration.

J. Faber, K. Siersbaek-Nielsen, T. Friis, 1987, Acta endocrinologica.

Primary haemostasis in thyroid disease

B. Myrup, J. Faber, C. Bregengård, 1995, Journal of internal medicine.

Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs.

S. Moestrup, H. Vorum, J. Gliemann, 1995, The Journal of clinical investigation.

Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.

O. Nordfang, C. Bregengård, P. Wildgoose, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits.

O. Svendsen, O. Nordfang, U. Hedner, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Relationships between serum thyrotropin, serum free thyroxine (T4), and 3,5,3'-triiodothyronine (T3) and the daily T4 and T3 production rates in euthyroid patients with multinodular goiter.

J. Faber, K. Siersbaek-Nielsen, T. Friis, 1987, The Journal of clinical endocrinology and metabolism.

Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.

J. Mehta, W. Nichols, T. Saldeen, 1995, Journal of the American College of Cardiology.